Conavi Medical (CNVI) Submits Novasight Hybrid Intravascular Imaging System to US FDA for Clearance скачать в хорошем качестве

Conavi Medical (CNVI) Submits Novasight Hybrid Intravascular Imaging System to US FDA for Clearance

This video is produced on behalf of the presenting company. Emerging Hybrid Intracoronary Imaging Technologies and Their Applications in Clinical Practice and Research https://www.jacc.org/doi/abs/10.1016/... Conavi Medical Submits Next Generation Novasight Hybrid Intravascular Imaging System to US FDA for 510(k) Clearance 2025-09-16 16:34 ET - News Release US FDA 510(k) Submission Follows the Successful Validation Testing with KOLs FDA 510(k) Clearance Anticipated During H1 2026 and Company Preparing for US Commercial Launch following Clearance Coronary Intravascular Imaging Market Expected to Grow to over $1 bil USD by 2028 TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, announced that it has submitted its next generation Novasight Hybrid™ IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (“FDA”) for 510(k) clearance for coronary applications. Martin Gagel and Market Radius Capital, Inc. are not registered or licensed to provide investment advice. Content is for information purposes only and may include incomplete or incorrect information and is not advice or a recommendation. Communications and content from Radius Research or Market Radius Research are productions of Market Radius Capital, Inc. Martin Gagel may own shares of any of the companies mentioned. Market Radius Capital, Inc. may be compensated and may have commercial arrangements with any of the companies mentioned. Content may contain forward looking statements. Please read the presenting companies' forward looking statement disclaimers.